Nexstim PLC NXTMH
OMXHEX · Finland · Health Technology
€9.47-0.07 (-0.73%)
Market closed· · EUR · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · EUR · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
Nexstim Oyj (STU:5NX) reports strong H1 2026 results with a 16% revenue increase, driven by a 144% surge in Research and Neuroscience, while maintaining a robust 80% gross margin and positive EBITDA.
As European markets show modest gains, with the STOXX Europe 600 Index advancing slightly and major indexes in Germany, France, and Italy rising, investors are closely monitoring developments such as the U.S.-Iran agreement's potential impact on energy prices. Amidst this backdrop of cautious optimism and persistent supply shocks highlighted by the ECB, identifying stocks that may be trading at a discount can provide opportunities for those looking to capitalize on undervaluation in a market...
As European markets navigate the complexities of geopolitical developments and economic adjustments, indices like the STOXX Europe 600 have shown modest gains amid investor anticipation of a U.S.-Iran agreement. In this environment, identifying stocks that may be trading below their estimated value becomes crucial for investors seeking opportunities in undervalued assets. A good stock in such conditions often exhibits strong fundamentals and resilience to external shocks, offering potential...
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.